EGAGenomicsIllumina HumanWG-6Otherhttps://ega-archive.org/studies/EGAS00001002520EGAEGA study EGAS00001002520LITSEGArestrictedResearch and Development, Activities, Priorities, Priority, Activity, Effects, Longterm, Research, Laboratory, Long Term Effects, Longterm Effect, Long-Term Effect, Statistic, Research Priorities, Development and Research, Research Priority, Research Activity, Long-Term, Effect, Laboratory Research, Long-Term Effects, Research Activities., Long Term, Longterm Effectsmalignant tumor of the breast, dmBest1, Antemortem Diagnosis, Materials, determination, HSN1E, Metastasis, Gene Expression Profile, mammary neoplasm, Human Mammary Neoplasms, Neoplasm Metastases, Profiles, neoplasm metastasis, Tumor, Diagnosis, DmelCG6264, Long Term, prevention, cancer metastasis, Techniques, sampling, diseases, "neoplasm of breast (disorder)" EXACT [SNOMEDCT_2005_07_31:126926005], Method, Lifestyle Factor, symptoms, ARB, diseases and disorders, cancer of the breast, Effect, prevention and control, BC, Mammary Neoplasms, malignant neoplasm of breast, human disease, Gene Expressions, reference sample, Genomes, Comparative Genomics, Human Mammary Carcinomas, Statistic, procedures, Lifestyle, Signatures, preventive measures, allergic reaction, Methodological Studies, Expression Signature, malignant neoplasm, cancer of breast, Transcriptomes, Homo sapiens disease, Malignancies, Childbirths, mammary cancer, CXXC finger protein 9, Long-Term Effects, Diagnose, Tumors, screening, Carcinoma, Genomics, preventive therapy, anatomical protrusion, Papers, CG6264, "breast neoplasm" EXACT [MTH:120], Data Set, metastatic cancer, Comparative, Expression Profiles, Longterm Effect, Functional Genomics, Procedure, results, Diagnoses, Life Styles, Gene Expression, Postmortem, Screenings, Benign, Examinations and Diagnoses, Expression Signatures, Diseases, Genetic Materials, NOS, Postmortem Diagnosis, Expression Profile, TU15B, Malignant Neoplasm of Breast, Genetic Material, Transcriptome Profiles, dBest1, Carcinomas, Diagnoses and Examination, ADCADN, Postmortem Diagnoses, UNQ203/PRO229, DNA (cytosine-5-)-methyltransferase 1, dbest1, signs, Benign Neoplasms, Methodological, whole genome, "mammary neoplasm" RELATED [], Methodological Study, malignant metastatic neoplasm, Malignant Neoplasms, disease, metastatic, breast cancer, spine, Material, Breast Tumors, Breast Malignant Tumors, Cistron, cancer, Childbirth, other disease, primary breast cancer, Procedures, Effects, Transcriptome Profile, Neoplasms, Benign Neoplasm, number, Goal, Gene, Parturitions, Mammary Cancers, anon-WO0118547.380, Malignant, protrusion, Human, Aim, method, Breast Malignant Tumor, AIM, Structural, Births, sensitive, Breast Tumor, method used in an experiment, Functional, Mass, Studies, Screening, disease or disorder, "mammary tumor" EXACT [CSP2005:2016-0671], breast tumor, Antemortem, Technique, sensitivity, Lifestyle Factors, DNMT1, tumor cell migration, Human Mammary, Genetic, DNMT1_HUMAN, Malignancy, Longterm, Birth, Mammary Neoplasm, VMD2, Profile, Mammary Carcinoma, metastasis, Long-Term, Diagnoses and Examinations, BMD, Expressions, Probabilities, Cancer of the Breast, non-neoplastic, Study, Neoplasias, API6, Malignant Tumor of Breast, Mammary, Mammary Cancer, disorder, Long-Term Effect, Expression, Breast, mammary tumor, tumor metastasis, Controlled, DNA MTase HsaI, Cancer, RP50, DNA (cytosine-5)-methyltransferase 1, Antemortem Diagnoses, Breast Carcinoma, Human Mammary Neoplasm, Life Style Induced Illness, Controlling, findings, Transcriptome, Breast Carcinomas, Malignant Neoplasm, whole blood, metastatic malignant neoplasm, malignant, Metastases, disorders, DNMT, Random, medical condition, Factor, MCMT, "breast tumor" EXACT [NCI2004_11_17:C2910], Cistrons, Examination and Diagnoses, metastatic neoplasm, Breast Malignant Neoplasm, Metastase, MT, cancer diagnosis, Mammary Carcinomas, Mass Screenings, DNA methyltransferase HsaI, chemical analysis, Long Term Effects, Gene Expression Signatures, Neoplasm, condition, Human Mammary Carcinoma, Gene Expression Signature, background, techniques, Lifestyles, CXXC9, Dbest, primary cancer, Breast Neoplasm, CT-2, best, prophylaxis, Randomization, Allocation, Cancers, Breast Malignant Neoplasms., CXXC-type zinc finger protein 9, malignant tumor, introduction, Longterm Effects, plan specification, sample collection, control, Gene Expression Profiles, Breast Cancer, cardinality, Structural Genomics, Cancer of Breast, assay, Signature, BEST, CLEC2C, Neoplasia, breast, m.HsaI, methodologyfalseLocal In Time Statistics for processual researchBackground: Functional genomics in a processual analysis cover the time-dependent changes in transcriptomics and epigenetics before diagnosis of a disease, reflecting the changes in both life style and disease processes. The aim of this paper is to explore the dynamic, time-dependent mechanisms of the metastatic processes, using blood transcriptomics and including time in a continuous manner. For achieving this goal we develop new statistical methods based on statistics that are local in time. Methods: The new statistical method, Local In Time Statistics (LITS), is based on calculating statistics in moving windows and randomization. The method has been tested for the analysis of a dataset that collectively provides information on the blood transcriptome up to eight years before breast cancer diagnosis. The dataset from the NOWAC Post-genome Cohort consists of 467 case-control pairs matched on birth year and time of blood sampling. The data for a pair is the difference in log2 gene expression between the case and control. The stratified analyses are based on important biological differences like metastatic versus non-metastatic cancer, and the mode of cancer detection, i.e. screening detected versus clinically detected cancers. The dataset was used for examining whether the gene expression profile varies between cases and controls, with time, or between cases with and without metastases. Results: The null hypotheses of no differences between cases and controls, no time-dependent changes, and no differences between different strata were all rejected. For screening detected cancers the probability of correct prediction of metastasis status was best in year 1 before diagnosis compared to year 3 and 4 before diagnosis for clinically detected cancers. The predictor was not very sensitive to the number of genes included.Conclusions: Using a new statistical method, LITS, we have demonstrated time-dependent changes of the blood transcriptome up to eight years before breast cancer diagnosis.2017-09-26 10:50:51EGAS000010025209606EGAD00010001400EGAC00001000684